Palatin Technologies, Inc. — Form 10-Q Summary
Business context and reporting period
Biopharmaceutical company developing peptide therapeutics. The filing covers the quarter and six months ended December 31, 2011, Palatin’s fiscal second quarter. Bremelanotide for female sexual dysfunction (FSD) was in Phase 2B; inhaled PL-3994 for acute asthma was in preclinical research. AstraZeneca was developing AZD2820 for obesity under a collaboration.
Financial performance and position
- Revenue: $11,492 for the quarter and $38,709 for the six months, down from $1.04 million and $1.26 million, respectively, in the prior-year periods. The earlier periods included $846,768 of grant revenue; no grant revenue was recorded in 2011. All license and contract revenue was from AstraZeneca.
- Operating results: Quarterly operating loss was $3.70 million versus $1.83 million; six-month operating loss was $7.07 million versus $6.45 million. Net loss was $2.62 million for the quarter and $5.98 million for six months, compared with $1.10 million and $5.70 million, respectively. Quarterly and six-month loss per share was $0.08 and $0.17, versus $0.09 and $0.48.
- Expenses: R&D was $2.69 million for the quarter and $4.98 million for six months; quarterly spending rose year over year, mainly due to the ongoing bremelanotide trial, while six-month R&D declined. G&A was $1.02 million for the quarter and $2.13 million for six months. Gross margin is not applicable to the reported development-stage operations.
- Cash flow: Operating activities used $6.95 million in the six months, versus $5.21 million a year earlier. Cash decreased $6.97 million to $11.90 million. Investing cash flow was $3,000 provided; financing cash flow was $20,743 used.
- Liquidity and debt: Current assets were $13.78 million, including $11.90 million cash and $1.07 million receivable; current liabilities were $2.21 million. Total liabilities were $2.33 million, including capital lease obligations of about $56,000. The $1.07 million receivable from the sale of New Jersey net operating loss carryforwards was collected January 3, 2012.
Material changes and unusual items
- Revenue fell primarily because the prior-year period included a federal grant that was fully recognized by June 2011; AstraZeneca contract revenue also declined.
- The company recognized a $1.07 million income tax benefit in the quarter from selling New Jersey state net operating loss carryforwards. The comparable prior-year quarter included a $637,391 benefit from such a sale.
- Cash and cash equivalents declined from $18.87 million at June 30, 2011 to $11.90 million at December 31, 2011. The company reported no common shares issued during the six-month period; it did issue warrants for up to 200,000 shares to a financial adviser in November 2011.
Outlook, risks, and contingencies
Management said existing cash and receivables were expected to fund planned operations, including the ongoing bremelanotide Phase 2B trial, through at least calendar 2012. Phase 3 trials, which management said would not begin before 2013, will require significant additional capital. The company expects continued losses and a significant loss for fiscal 2012; profitability is uncertain. It is prioritizing bremelanotide and limiting PL-3994 work, and will not substantially fund other programs without additional financing or collaboration support. Funding may be unavailable or available only on unfavorable terms, potentially requiring earlier partnerships or disposition of product rights. Product development, clinical and regulatory success, commercialization, and dependence on collaboration revenue remain key risks. The filing reports no current legal proceedings and no material change to previously disclosed risk factors.
Important facts for investors to verify
- Whether bremelanotide’s Phase 2B trial progresses as planned and what results, timing, and costs management later reports.
- Cash burn and runway, including the effect of the January 2012 receipt and funding needs for Phase 3.
- Availability and terms of financing or partnerships for bremelanotide, PL-3994, and other programs.
- Future AstraZeneca-related revenue and any development, regulatory, or sales milestones and royalties.
- Potential dilution from outstanding options, warrants, preferred shares, and the newly issued financial-adviser warrants.